Heidelberg Biolabs GmbH is a spin-off company of the German Cancer Research Center (DKFZ) founded in 2019 with the aim to commercialize the advanced methods for extracellular circulating (cell-free) nucleic acids analysis. We currently offer a line of research kits for extracellular RNA isolation, quality control and ultrasensitive detection with RT-qPCR as well as high-throughput sequencing. In addition, we are working on establishing innovative tests for early diagnostics of various disorders based on cell-free RNA and DNA biomarkers. The company is currently located at the Heidelberg Technology Park and the National Center for Tumor Diseases (NCT) - internationally renowned hubs for innovation and liquid biopsies analysis.

The research products and services offered by Heidelberg Biolabs and our sales partner Nucleus Biotech are based on thoroughly optimized protocols and various know-how developed at the German Cancer Research Center and University Hospital Heidelberg over the last decade. Our methodology secures the analysis of ultra-low RNA inputs with unprecedented efficacy, sensitivity, and robustness.

Our translational research initiative is being realized in the form of an innovative "Mi-Test" for preventive diagnostics of multiple pathological conditions based on extracellular RNA signatures in human blood and other biological fluids. The current version of Heidelberg Biolabs "Mi-Test" implies qPCR-based measurement of several miRNAs expressed exclusively in the myocardial cells, and which presence in the blood plasma can be a smart indicator of the ongoing cell death in the myocardium. Such surveillance of the health status by measuring organ-specific miRNAs (along with other circulating RNA species) in biofluids can be performed at point-of-care stations complementing the conventional blood tests in the future.

OUR GOALS

• To foster fundamental research and development in the field of extracellular nucleic acids.
• To facilitate the discovery of novel biomarkers based on circulating nucleic acids in liquid biopsies.
• To enable preventive diagnostics of human pathologies using tissue-specific RNA signatures in biofluids.
• To launch an approved test for monitoring human health status by detecting myocard-specific miRNAs in the blood.